Cervical cancer in the Maghreb country (Morocco - Algeria - Tunisia) : epidemiological, clinical profile and control policy

##plugins.themes.academic_pro.article.sidebar##

Published Nov 14, 2018
Download
pdf
Vol. 96 No. 10 (2018): Issue Oct 2018

##plugins.themes.academic_pro.article.main##

Ikram YAZGHICH
Mohamed BERRAHO

Abstract


Introduction: Cervical cancer is a public health problem in the Maghreb countries with high mortality and socio-economic impact. The objective of this subject is exposed the epidemiological profile, programs of prevention and the support of cervical cancer in Maghreb (Morocco, Tunisia and Algeria).
Methods: To implement this work, we carried out research on morbidity and mortality; cancer plans for Maghreb countries (Morocco, Algeria and Tunisia); cervical cancer surveillance for each country; the prevention programs of cervical cancer including vaccination, screening, information campaigns, awareness and education; and research conducted in Morocco, Algeria and Tunisia.
We interviewed databases (Pubmed, Sciences Direct etc.), ministerial website, World Health Organization website, foundations website and centers of cancer research.
Results: The cervical cancer (CC) is diagnosed at advanced stages. The majority of patients are in advanced stages (stage II, III and IV). Regarding the histological profile squamous cell carcinoma is predominant. HPV 16 and HPV 18 single or multiple infection are by far the most common types of HPV associated with CCU in the Maghreb countries concerning the microbiological profile. All three countries have set up a cancer plans to prevent and control this disease and these impacts. Among the strong points of health policy in cancerology, in all three countries, we raised the existence of a cancer registry for monitoring and evolution of disease. Regarding the prevention of CC, in the three Maghreb countries, there is no primary prevention program (HPV vaccine and the struggle against risk factors), much deficiencies about secondary and tertiary prevention.
Conclusion : To win the fight against the CC, the Maghreb countries are called to strengthen the health system globally, to consolidate the national policy and the national guidelines to fight against the CC and to allocate the financial and technical resources to support the implementation policy and guidelines to make services accessible and affordable for women and girls.

Keywords:

Cervical Cancer - Epidemiology - Prevention - Screening - Program - Morocco - Algeria - Tunisia

##plugins.themes.academic_pro.article.details##

References

  1. Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol Off J Eur Soc Med Oncol. déc 2011;22(12):2675‑86.
  2. Globoccan 2012. International Agency for Research for Cancer. Worl Health Organisation.
  3. Cancer today. International agengy for research on cancer (IARC). World health organisation (WHO). Disponible à : http://gco.iarc.fr/today/home
  4. La lutte contre le cancer du col de l'utérus : Guide des pratiques essentielles. OMS Deuxième édition 2017.
  5. Hillemanns P, Soergel P, Hertel H, Jentschke M. Epidemiology and Early Detection of Cervical Cancer. Oncol Res Treat. 2016;39(9):501-6.
  6. Rapport 2008-2012. Registre des Cancers du Grand Casablanca.
  7. Rapport du Réseau National des Registres du Cancer - Algérie 2015
  8. Gobrane HL-B, Hajjem S, Aounallah-Skhiri H, Achour N, Hsairi M. Mortalité par cancer en Tunisie : calcul des années de vies perdues, Summary. Santé Publique. 17 mai 2011;23(1):31‑40.
  9. Plan national de prévention et de contrôle du cancer 2010 - 2020. Fondation Lalla Salma Ministère de la Santé Maroc 24 Mars 2010.
  10. Plan pour la lutte contre le cancer 2015 - 2019, Ministère de la santé Tunisie février 2015.
  11. Plan national du cancer, Ministère de la santé Algérie 2014.
  12. Znaor A, Eser S, Anton-Culver H, Fadhil I, Ryzhov A, Silverman BG, et al. Cancer surveillance in northern Africa, and central and western Asia: challenges and strategies in support of developing cancer registries. Lancet Oncol. 1 févr 2018;19(2):e85‑92.
  13. Missaoui N, Hmissa S, Trabelsi A, Tahar Yacoubi M, Nouira A, Frappart L, et al. Prévalence des infections à papillomavirus (HPV) dans les lésions précancéreuses et cancéreuses du col utérin en Tunisie. Ann Biol Clin (Paris). 1 mai 2010;68(3):297‑303.
  14. Nabiha Missaoui1, Sihem Hmissa, Amel Trabelsi , Lucien Frappart , Moncef Mokni , Sadok Korbi. Cervix Cancer in Tunisia: Clinical and Pathological Study. Asian Pacific J Cancer Prev, 2010 ; 11, 235-238
  15. Mohamed Berraho, Karima Bendahhou , Majdouline Obtel , Ahmed Zidouh , Abdellatif Benider , Hassan Errihani , Chakib Nejjari. Cervical Cancer in Morocco: Epidemiological Profile from Two Main Oncological Centers. Asian Pacific J Cancer Prev, 2012 ; 13, 3153-3157.
  16. Elmajjaoui S, Ismaili N, El Kacemi H, Kebdani T, Sifat H, Benjaafar N. Epidemiology and outcome of cervical cancer in national institute of Morocco. BMC Womens Health. 13 sept 2016;16:62.
  17. Boublenza L, Hadef K, Beldjillali H, Chabni N, Reguegba D, Meguenni K. Épidémiologie du cancer du col de l'utérus dans une région de l'Ouest algérien entre 2006 et 2010. Médecine Santé Trop. 1 avr 2013;23(2):232‑3.
  18. Mahcene A. 21/06/2016 . Etude épidémiologique du cancer du col de l'utérus dans l'Est algérien. Mémoire présenté en vue de l'obtention du Diplôme de Master Domaine : Sciences de la Nature et de la Vie.
  19. Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 13 janv 2003;88(1):63‑73.
  20. Sancho-Garnier H, Khazraji YC, Cherif MH, Mahnane A, Hsairi M, El Shalakamy A, et al. Overview of cervical cancer screening practices in the extended Middle East and North Africa countries. Vaccine. 30 déc 2013;31 Suppl 6:G51-57.
  21. Berraho M. Thèse nationale scientifique. Epidémiologie du cancer du col au Maroc. Université Victor Segalen Bordeaux 2 France. Décembre 2012.
  22. Guide de détection précoce du cancer du sein et du col au Maroc. Ministère de la Santé. Edition 2011.
  23. Manuel de Prise en charge Du cancer du col de l'utérus. MS Algérie Février 2016.
  24. KrennHrubec K, Mrad K, Sriha B, Ben Ayed F, Bottalico DM, Ostolaza J, et al. HPV Types and Variants Among Cervical Cancer Tumors in Three Regions of Tunisia. J Med Virol. avr 2011;83(4):651‑7.
  25. Ennaifer E, Tounsi H, Ben Aissa R, Kalai K, Fehri E, Laassili T, Guizani I, Boubaker MS. Détection de l'infection à papillomavirus humain chez des consultantes d'un centre tunisien de recherche de la sante de la reproduction. La tunisie Medicale - 2014 ; 92 (4) : 253-257
  26. Ennaifer E, Salhi F, Laassili T, Fehri E, Ben Alaya N, Guizani I, et al. Type-Specific Human Papillomavirus Distribution in Invasive Squamous Cervical Carcinomas in Tunisia and Vaccine Impact. Asian Pac J Cancer Prev APJCP. 2015;16(15):6769‑72.
  27. Ardhaoui M, Ennaifer E, Letaief H, Salsabil R, Lassili T, Chahed K, et al. Prevalence, Genotype Distribution and Risk Factors for Cervical Human Papillomavirus Infection in the Grand Tunis Region, Tunisia. PloS One. 2016;11(6):e0157432.
  28. Berraho M, Amarti-Riffi A, El-Mzibri M, Bezad R, Benjaafar N, Benideer A, et al. HPV and cofactors for invasive cervical cancer in Morocco: a multicentre case-control study. BMC Cancer. 2017 Jun 20;17(1):435.
  29. Ghedira R, Mahfoudh W, Hadhri S, Gabbouj S, Bouanene I, Khairi H, et al. Human papillomavirus genotypes and HPV-16 variants distribution among Tunisian women with normal cytology and squamous intraepithelial lesions. Infect Agent Cancer. 2016;11:61.
  30. Hussein WM, Anwar WA, Attaleb M, Mazini L, Försti A, Trimbitas R-D, et al. A review of the infection-associated cancers in North African countries. Infect Agent Cancer. 2016;11:35.
  31. Nahet A, Boublenza L, Hassaine H, Masdoua N, Prétet J-L, Belglaiaa E, et al. Le génotypage d'ADN d'HPV : une étude de cancers ano-génitaux, de cancers des VADS et de cancers cutanés dans la population de l'ouest algérien. Détection d'HPV dans différents cancers dans la population de l'ouest algérien. Bull Cancer (Paris). 1 mai 2016;103(5):455‑60.
  32. Zidi S, Sahli M, Mezlini A, Yacoubli-Loueslati B. Association of Combined Tobacco Smoking, Hormonal Contraceptive use and Status Matrimonial with Cervical Cancer Evolution in Tunisian Women. Pathol Oncol Res POR. 5 juin 2018;
  33. Masdoua N, Boublenza L, Hassaine H, Ngou J, Nahet A, Segondy M, et al. Characteristics of HPV infection in women at risk in Western Algeria. Med Mal Infect. févr 2017;47(1):38‑41.
  34. Hammouda D, Muñoz N, Herrero R, Arslan A, Bouhadef A, Oublil M, et al. Cervical carcinoma in Algiers, Algeria: Human papillomavirus and lifestyle risk factors. Int J Cancer. 113(3):483‑9.
  35. Berraho M, Fakir SE, Abda N, Mathoulin-Pelissier S, Nejjari C. Connaissances et pratiques des médecins vis-à -vis du cancer du col de l'utérus et de l'infection HPV à Fès, HPV and cervical cancer: knowledge and practices of physicians in Fez. Santé Publique. 2013;25(3):351‑7.
  36. Messoudi W, El Mahi T, Diaz Sanchiz M, Saadani G, Zidouh A, Nejjari C, et al. Cost-effectiveness of HPV vaccine introduction in Morocco. RESP. 2018;66:S160.
  37. Zidi S, Gazouani E, Stayoussef M, Mezlini A, Ahmed SK, Yacoubi-Loueslati B, et al. IL-10 gene promoter and intron polymorphisms as genetic biomarkers of cervical cancer susceptibility among Tunisians. Cytokine. 2015;76(2):343‑7.
  38. Zidi S, Sghaier I, Zouidi F, Benahmed A, Stayoussef M, Kochkar R, et al. Interleukin-1 Gene Cluster Polymorphisms and its Haplotypes may Predict the Risk to Develop Cervical Cancer in Tunisia. Pathol Oncol Res POR. 2015;21(4):1101‑7.
  39. Zidi S, Stayoussef M, Zouidi F, Benali S, Gazouani E, Mezlini A, et al. Tumor Necrosis Factor Alpha (-238 / -308) and TNFRII-VNTR (-322) Polymorphisms as Genetic Biomarkers of Susceptibility to Develop Cervical Cancer Among Tunisians. Pathol Oncol Res POR. 2015;21(2):339‑45.
  40. Fyles AW, Pintilie M, Kirkbride P, et al. Prognostic factors in patients with cervix cancer treated by radiation therapy: results of a multiple regression analysis. Radiother Oncol, 1995;35, 107-17.
  41. Barillot I, Horiot JC, Pigneux J, et al. Carcinoma of the intact uterine cervix treated with radiotherapy alone: a French cooperative study: update and multivariate analysis of prognostics factors. Int J Radiat Oncol Biol Phys, 1997;38, 969-78.
  42. Perez CA, Grigsby PW, Nene SM, et al (1992). Effect of tumor size on the prognosis of carcinoma of the uterine cervix treated with irradiation alone. Cancer, 69, 2796-806. Perez CA, Hoskins WJ, Yung RC. Principles and Practice of Gynecological Oncology. Philadelphia, J.B. Lippincott Company 1997.
  43. Activity report. National Cancer Institute USA, 2009.
  44. Fagundes H, Perez CA, Grigsby PW, Lockett MA. Distant metastases after irradiation alone in carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys, 1992;24, 197-204
  45. Karimi Zarchi M, Akhavan A, Fallahzadeh H, et al. Outcome of Cervical Cancer in Iranian Patients According to Tumor Histology, Stage of Disease and Therapy. APJCP, 2010;11, 1289-91.
  46. Gien LT, Beauchemin MC, Thomas G, Adenocarcinoma. A unique cervical cancer. Gynecol Oncol, 2010;116, 140-6.
  47. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human HPV is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-9
  48. Chaouki N, Bosch FX, Muñoz N, Meijer CJ, El Gueddari B, El Hazi A, et al. The viral origin of cervical cancer in Rabat, Morocco. Int J Cancer. 1998;75:546-54
  49. Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human HPV types in invasive cervical cancer worldwide: a metaanalysis. Br J Cancer. 2003;88:63-7.
  50. Odida M, Sandin S, Mirembe F, Kleter B, Quint W, Weiderpass E. HPV types, HIV and invasive cervical carcinoma risk in Kampala, Uganda: a case-control study. Infect Agent Cancer. 2011;25:6-8